Home › Research › Cognitive tests and assessment
Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia
Hager K, Marahrens A, Kenklies M, Riederer P, Münch G.. Archives of gerontology and geriatrics, 2001-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Oxidative stress and energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD), thus antioxidants with positive effects on glucose metabolism such as thioctic (alpha-lipoic) acid should exert positive effects in these patients. Therefore, 600 mg alpha-lipoic acid was given daily to nine patients with AD and related dementias (receiving a standard treatment with acetylcholinesterase inhibitors) in an open study over an observation period of, on avarage, 337+/-80 days. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (mini-mental state examination: MMSE and AD assessment scale, cognitive subscale: ADAScog).
What this study adds
Evidence grade: High
In this open study, nine patients with Alzheimer's disease and related dementias taking standard acetylcholinesterase inhibitors received 600mg alpha-lipoic acid daily for an average of about 337 days, and cognitive scores stayed constant. Because the study was open and involved only nine patients, it cannot establish whether alpha-lipoic acid slows or prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001). Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Archives of gerontology and geriatrics. https://doi.org/10.1016/s0167-4943(01)00104-2
Vancouver
Hager K, Marahrens A, Kenklies M, Riederer P, Münch G. Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Archives of gerontology and geriatrics. 2001. doi:10.1016/s0167-4943(01)00104-2. PMID: 11395173.
BibTeX
@article{hager2001-11395173,
author = {Hager, K. and Marahrens, A. and Kenklies, M. and Riederer, P. and Münch, G.},
title = {{Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia}},
journal = {Archives of gerontology and geriatrics},
year = {2001},
doi = {10.1016/s0167-4943(01)00104-2},
pmid = {11395173},
url = {https://doi.org/10.1016/s0167-4943(01)00104-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Therefore, 600 mg alpha-lipoic acid was given daily to nine patients with AD and related dementias (receiving a standard treatment with acetylcholinesterase inhibitors) in an open study over an observation period of, on avarage, 337+/-80 days.
- The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (mini-mental state examination: MMSE and AD assessment scale, cognitive subscale: ADAScog).
- Despite the fact that this study was small and not randomized, this is the first indication that treatment with alpha-lipoic acid might be a successful 'neuroprotective' therapy option for AD and related dementias.
Why it matters
In this open study, nine patients with Alzheimer's disease and related dementias taking standard acetylcholinesterase inhibitors received 600mg alpha-lipoic acid daily for an average of about 337 days, and cognitive scores stayed constant. Because the study was open and involved only nine patients, it cannot establish whether alpha-lipoic acid slows or prevents dementia.
Study details
- Evidence strengthHigh
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of gerontology and geriatrics) |
| Journal's citation record | 1 / 4 | Archives of Gerontology and Geriatrics: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 188 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 3 / 6 | Cited 6.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Gerald W Münch: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Würzburg: institution h-index 852 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11395173) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.